In addition, dupilumab, an IL4R‐blocking antibody, has shown clinical efficacy in the treatment of AD, and it's noteworthy that besides conjunctivitis/blepharitis, emerging dermatitis in the head and neck area is now recognized as a significant side effect, with an incidence of up to 10%.343. This evidence concerns the gene IL4R and skin disorder.